Anti-CTL1/ SLC44A1/ CD92 monoclonal antibody
Anti-CTL1/ SLC44A1/ CD92 antibody for FACS & in-vivo assay
Go to SLC44A1/SLC44A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1626-Ab-1/ GM-Tg-hg-MP1626-Ab-2 | Anti-Human SLC44A1 monoclonal antibody | Human |
| GM-Tg-rg-MP1626-Ab-1/ GM-Tg-rg-MP1626-Ab-2 | Anti-Rat SLC44A1 monoclonal antibody | Rat |
| GM-Tg-mg-MP1626-Ab-1/ GM-Tg-mg-MP1626-Ab-2 | Anti-Mouse SLC44A1 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1626-Ab-1/ GM-Tg-cynog-MP1626-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC44A1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1626-Ab-1/ GM-Tg-felg-MP1626-Ab-2 | Anti-Feline SLC44A1 monoclonal antibody | Feline |
| GM-Tg-cang-MP1626-Ab-1/ GM-Tg-cang-MP1626-Ab-2 | Anti-Canine SLC44A1 monoclonal antibody | Canine |
| GM-Tg-bovg-MP1626-Ab-1/ GM-Tg-bovg-MP1626-Ab-2 | Anti-Bovine SLC44A1 monoclonal antibody | Bovine |
| GM-Tg-equg-MP1626-Ab-1/ GM-Tg-equg-MP1626-Ab-2 | Anti-Equine SLC44A1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1626-Ab-1/ GM-Tg-hg-MP1626-Ab-2; GM-Tg-rg-MP1626-Ab-1/ GM-Tg-rg-MP1626-Ab-2; GM-Tg-mg-MP1626-Ab-1/ GM-Tg-mg-MP1626-Ab-2; GM-Tg-cynog-MP1626-Ab-1/ GM-Tg-cynog-MP1626-Ab-2; GM-Tg-felg-MP1626-Ab-1/ GM-Tg-felg-MP1626-Ab-2; GM-Tg-cang-MP1626-Ab-1/ GM-Tg-cang-MP1626-Ab-2; GM-Tg-bovg-MP1626-Ab-1/ GM-Tg-bovg-MP1626-Ab-2; GM-Tg-equg-MP1626-Ab-1/ GM-Tg-equg-MP1626-Ab-2 |
| Products Name | Anti-SLC44A1 monoclonal antibody |
| Format | mab |
| Target Name | SLC44A1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-SLC44A1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species CTL1/ SLC44A1/ CD92 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLPm004380 | mouse Slc44a1 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm004380 | mouse Slc44a1 Lentivirus particle |
Target information
| Target ID | GM-MP1626 |
| Target Name | SLC44A1 |
| Gene ID | 23446,100434,85254,715816,474792,101086097,538887,100060701 |
| Gene Symbol and Synonyms | 2210409B22Rik,4833416H08Rik,CD92,CDW92,CHTL1,CONATOC,CTL1,SLC44A1 |
| Uniprot Accession | Q8WWI5,Q8VII6 |
| Uniprot Entry Name | CTL1_HUMAN,CTL1_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000070214 |
| Target Classification | N/A |
The target: SLC44A1, gene name: SLC44A1, also named as CD92, CDW92, CHTL1, CTL1. Enables choline transmembrane transporter activity. Involved in choline transport and transmembrane transport. Located in several cellular components, including cytosol; mitochondrion; and nucleoplasm. Implicated in high grade glioma. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

